Arzneiwerk AG VIDA (STU:TLIK) Cyclically Adjusted Revenue per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TLIK Arzneiwerk AG VIDA STU:TLIK
40 GF Score
Price €0.22
! 7 Warning Signs
View Full Analysis

What is Arzneiwerk AG VIDA Cyclically Adjusted Revenue per Share?

Arzneiwerk AG VIDA STU:TLIK 40 Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus rates STU:TLIK with a GF Score™ of 40/100. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Arzneiwerk AG VIDA's adjusted revenue per share for the three months ended in Mar. 2026 was €0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Arzneiwerk AG VIDA's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Arzneiwerk AG VIDA was -6.80% per year. The lowest was -14.40% per year. And the median was -12.10% per year.

As of today (2026-08-31), Arzneiwerk AG VIDA's current stock price is €0.22. Arzneiwerk AG VIDA's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.00. Arzneiwerk AG VIDA's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arzneiwerk AG VIDA was 3.18. The lowest was 0.08. And the median was 0.46.


Arzneiwerk AG VIDA  (STU:TLIK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arzneiwerk AG VIDA was 3.18. The lowest was 0.08. And the median was 0.46.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Arzneiwerk AG VIDA Cyclically Adjusted Revenue per Share Related Terms


Arzneiwerk AG VIDA Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Arzneiwerk AG VIDA's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arzneiwerk AG VIDA Cyclically Adjusted Revenue per Share Chart

Arzneiwerk AG VIDA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.48 2.23 1.86 2.11 0.00

Arzneiwerk AG VIDA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.89 0.00 0.00 0.00

STU:TLIK vs MCK, COR, CAH: Cyclically Adjusted Revenue per Share Comparison

For the Medical Distribution subindustry, Arzneiwerk AG VIDA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arzneiwerk AG VIDA Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Arzneiwerk AG VIDA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arzneiwerk AG VIDA's Cyclically Adjusted PS Ratio falls into.


STU:TLIK
40GF Score
Arzneiwerk AG VIDA STU:TLIK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arzneiwerk AG VIDA Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arzneiwerk AG VIDA's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/131.2583*131.2583
=0.000

Current CPI (Mar. 2026) = 131.2583.

Arzneiwerk AG VIDA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.385 100.717 0.502
201609 0.553 101.017 0.719
201612 0.641 101.217 0.831
201703 0.656 101.417 0.849
201706 0.563 102.117 0.724
201709 0.336 102.717 0.429
201712 0.800 102.617 1.023
201803 0.375 102.917 0.478
201806 0.432 104.017 0.545
201809 0.192 104.718 0.241
201812 1.224 104.217 1.542
201903 0.539 104.217 0.679
201906 0.333 105.718 0.413
201909 0.120 106.018 0.149
201912 0.274 105.818 0.340
202003 0.285 105.718 0.354
202006 0.222 106.618 0.273
202009 0.140 105.818 0.174
202012 0.169 105.518 0.210
202103 0.124 107.518 0.151
202106 0.157 108.486 0.190
202109 0.104 109.435 0.125
202112 0.159 110.384 0.189
202203 3.129 113.968 3.604
202206 3.138 115.760 3.558
202209 3.033 118.818 3.351
202212 -8.875 119.345 -9.761
202303 2.366 122.402 2.537
202306 2.471 123.140 2.634
202309 2.379 124.195 2.514
202312 -6.948 123.773 -7.368
202403 0.001 125.038 0.001
202406 2.329 125.882 2.428
202409 2.374 126.198 2.469
202412 0.005 127.041 0.005
202503 0.006 127.779 0.006
202506 0.004 128.412 0.004
202509 0.000 129.255 0.000
202512 0.000 129.361 0.000
202603 0.000 131.258 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Arzneiwerk AG VIDA (STU:TLIK) has a Cyclically Adjusted Revenue per Share of €0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arzneiwerk AG VIDA and its competitors.
Is Arzneiwerk AG VIDA's Cyclically Adjusted Revenue per Share too high?
Arzneiwerk AG VIDA's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's Cyclically Adjusted Revenue per Share compare to MCK and COR?
Arzneiwerk AG VIDA's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Distribution company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Distribution industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arzneiwerk AG VIDA and its competitors. Arzneiwerk AG VIDA's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (STU:TLIK) has a current Cyclically Adjusted Revenue per Share of €0.00. The current Cyclically Adjusted Revenue per Share is €0.00. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Arzneiwerk AG VIDA (STU:TLIK), the current Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arzneiwerk AG VIDA Business Description

Other Exchanges TLIK:GermanyTLIK:Germany
Address Ordensmeisterstrasse 15-16, Berlin, DEU, 12099
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score

Get the complete analysis for STU:TLIK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.22
Price